Currently, phase I and phase II clinical trials using anti-TIGIT mAbs, alone or combined with anti-PD-1/PD-L1 mAbs, are ongoing to evaluate the safety and efficacy in patients with metastatic or locally advanced solid tumors, such as RCC, NSCLC, SCCHN, breast cancer, melanoma, and CRC (NCT02794571, NCT03119428, NCT03563716, NCT03628677, NCT04047862). The gene discussed is CD274; the disease is renal cell carcinoma.